论文部分内容阅读
了解使用氧气驱动雾化吸入疗法治疗尘肺病合并肺部感染的不良反应,为进一步推动该方法的临床应用辅以佐证。将55例尘肺病合并肺部感染患者分为雾化组(氧气驱动雾化吸入组)、非雾化组(静脉给药组),观察不良反应的发生情况,两组之间在性别、年龄、病情程度、抗感染用药等方面基本一致。结果显示,与非雾化组比较,雾化组发生胸闷、憋气、心慌、刺激性咳嗽、咳痰等症状加重的不良反应无明显变化,心率、呼吸也无明显差异,两组各指标比较,差异均无统计学意义(P>0.05)。提示,氧气驱动雾化吸入疗法不导致所观察的不良反应。
Understand the use of oxygen-driven aerosol inhalation therapy for pneumoconiosis pneumoconiosis with adverse reactions, to further promote the clinical application of this method. Fifty-five patients with pneumoconiosis and pulmonary infection were divided into the atomization group (aerosol driven inhalation group) and the non-atomized group (intravenous administration group) to observe the incidence of adverse reactions. The differences in gender, age , The severity of the disease, anti-infection medication and other aspects are basically the same. The results showed that compared with non-atomized group, there was no significant change in adverse reactions such as chest tightness, suffocation, palpitation, irritating cough, expectoration and other symptoms in the nebulized group, no significant difference in heart rate and respiration, There was no significant difference (P> 0.05). Tip, oxygen-driven inhalation therapy does not lead to the observed adverse reactions.